DBV Technologies’ (DBVT) “Overweight” Rating Reiterated at Morgan Stanley
DBV Technologies S.A. (NASDAQ:DBVT)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Morgan Stanley in a research report issued on Monday.
A number of other analysts also recently weighed in on the company. Zacks Investment Research upgraded DBV Technologies from a “sell” rating to a “hold” rating in a report on Thursday, April 6th. Deutsche Bank AG initiated coverage on DBV Technologies in a report on Friday, June 23rd. They set a “buy” rating and a $46.00 price target for the company. Jefferies Group LLC reiterated a “buy” rating and set a $47.00 price target on shares of DBV Technologies in a report on Thursday, March 16th. Leerink Swann reiterated an “outperform” rating on shares of DBV Technologies in a report on Wednesday, March 15th. Finally, Societe Generale upgraded DBV Technologies from a “hold” rating to a “buy” rating in a report on Thursday, March 16th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $47.00.
Shares of DBV Technologies (NASDAQ:DBVT) opened at 38.02 on Monday. The company’s 50 day moving average price is $34.16 and its 200-day moving average price is $34.70. The firm’s market capitalization is $1.75 billion. DBV Technologies has a 52 week low of $31.87 and a 52 week high of $38.41.
TRADEMARK VIOLATION WARNING: “DBV Technologies’ (DBVT) “Overweight” Rating Reiterated at Morgan Stanley” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/07/10/dbv-technologies-s-a-dbvt-earns-overweight-rating-from-morgan-stanley.html.
Several hedge funds have recently modified their holdings of the stock. Alliancebernstein L.P. increased its stake in shares of DBV Technologies by 21.1% in the first quarter. Alliancebernstein L.P. now owns 996,535 shares of the company’s stock valued at $35,098,000 after buying an additional 173,798 shares in the last quarter. Jennison Associates LLC increased its stake in shares of DBV Technologies by 0.7% in the first quarter. Jennison Associates LLC now owns 537,726 shares of the company’s stock valued at $18,939,000 after buying an additional 3,577 shares in the last quarter. Morgan Stanley increased its stake in shares of DBV Technologies by 89.9% in the first quarter. Morgan Stanley now owns 249,988 shares of the company’s stock valued at $8,805,000 after buying an additional 118,317 shares in the last quarter. Exane Asset Management increased its stake in shares of DBV Technologies by 11.3% in the first quarter. Exane Asset Management now owns 137,606 shares of the company’s stock valued at $4,846,000 after buying an additional 13,920 shares in the last quarter. Finally, Marshall Wace North America L.P. purchased a new stake in shares of DBV Technologies during the first quarter valued at approximately $3,566,000. Institutional investors own 48.23% of the company’s stock.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.